Drug delivery vehicle

Abstract

The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

1 - 67 . (canceled) 
     
     
         68 . A targeted drug delivery vehicle comprising:
 a drug composition and 5-50 of a targeted poly-amino-acid subunit,   wherein the targeted poly-amino-acid subunit comprises a targeting amino acid chain conjugated to a fatty acid, and   wherein the targeting amino acid chain is 15-20 amino acids of an apolipoprotein A-1 and binds to a SR-B1 receptor.   
     
     
         69 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18, 19, 20, 21, 22, 23, 24, 25, or 26. 
     
     
         70 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 27, 28, 29, 30, 31, 32, 33, or 34. 
     
     
         71 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 35, 36, 37, 38, 39, 40, 41, or 42. 
     
     
         72 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 43, 44, 45, 46, 47, 48, 49, 50, or 51. 
     
     
         73 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 52, 53, 54, 55, 56, 57, 58, or 59. 
     
     
         74 . The targeted drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 60, 61, 62, 63, 64, 65, or 66. 
     
     
         75 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid chain is 1-15 carbons in length. 
     
     
         76 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid chain is a myristic acid. 
     
     
         77 . The target drug delivery vehicle of  claim 68 , wherein targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is an unesterified cholesterol. 
     
     
         78 . The target drug delivery vehicle of  claim 68 , wherein targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a palmitoyl-oleyl phosphatidylcholine. 
     
     
         79 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a phospholipid. 
     
     
         80 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is SEQ ID NOs.: 18-65, or 66, and wherein the fatty acid is a saturated fatty acid. 
     
     
         81 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain is covalently linked to the fatty acid. 
     
     
         82 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain comprises one or more amphipathic alpha-helical domains. 
     
     
         83 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to a transmembrane molecule. 
     
     
         84 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to an HDL receptor. 
     
     
         85 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has affinity to rapidly dividing cells. 
     
     
         86 . The target drug delivery vehicle of  claim 68 , wherein the targeting amino acid chain further comprises an amino acid sequence that has enhanced affinity to a cancer cell. 
     
     
         87 . The target drug delivery vehicle of  claim 68 , wherein the targeted drug delivery vehicle further comprises one or more compounds selected from the group consisting of: an unesterified cholesterol, a palmitoyl-oleoyl phosphatidylcholine, a phospholipid, an apolipoprotein A-1 protein, and a 15-20 amino acid chain of an apolipoprotein A-1 and binds to a SR-B1 receptor.